Akero Therapeutics (AKRO) Competitors $51.76 -0.97 (-1.84%) Closing price 04:00 PM EasternExtended Trading$51.63 -0.13 (-0.25%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, QGEN, ASND, BBIO, and BPMCShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Akero Therapeutics vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris QIAGEN Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation. Do analysts prefer ITCI or AKRO? Intra-Cellular Therapies currently has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Akero Therapeutics has a consensus target price of $82.50, suggesting a potential upside of 59.39%. Given Akero Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akero Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of ITCI or AKRO? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ITCI or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Akero Therapeutics N/A -15.19%-13.97% Does the media favor ITCI or AKRO? In the previous week, Akero Therapeutics had 9 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 10 mentions for Akero Therapeutics and 1 mentions for Intra-Cellular Therapies. Akero Therapeutics' average media sentiment score of 0.84 beat Intra-Cellular Therapies' score of 0.29 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akero Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ITCI or AKRO? Intra-Cellular Therapies has higher revenue and earnings than Akero Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Akero TherapeuticsN/AN/A-$252.06M-$1.95-26.54 Which has more volatility and risk, ITCI or AKRO? Intra-Cellular Therapies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500. SummaryAkero Therapeutics beats Intra-Cellular Therapies on 8 of the 15 factors compared between the two stocks. Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.20B$2.97B$5.63B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-26.5420.2228.5719.58Price / SalesN/A294.48424.4094.43Price / CashN/A43.1536.0257.93Price / Book4.817.568.135.54Net Income-$252.06M-$55.11M$3.24B$257.73M7 Day Performance2.76%7.56%2.03%0.95%1 Month Performance-6.94%11.47%8.29%10.68%1 Year Performance88.56%0.88%28.40%15.67% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics3.5262 of 5 stars$51.76-1.8%$82.50+59.4%+105.3%$4.20BN/A-26.5430ITCIIntra-Cellular Therapies0.9172 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560News CoverageGMABGenmab A/S3.9084 of 5 stars$20.52+1.1%$37.60+83.2%-20.7%$13.02B$3.12B11.662,682Positive NewsAnalyst UpgradeAnalyst RevisionRDYDr. Reddy's Laboratories2.3979 of 5 stars$15.08flat$16.95+12.4%-8.4%$12.59B$325.54B22.8527,811Positive NewsMRNAModerna4.259 of 5 stars$29.90-1.9%$46.61+55.9%-72.9%$11.79B$3.24B-3.425,800Analyst ForecastRGCRegencell Bioscience0.2793 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Gap DownHigh Trading VolumeVTRSViatris2.8868 of 5 stars$9.20-1.3%$10.40+13.0%-18.7%$10.94B$14.74B-2.9032,000News CoverageQGENQIAGEN3.5802 of 5 stars$47.49-1.8%$49.40+4.0%+17.7%$10.75B$1.98B119.075,765ASNDAscendis Pharma A/S3.694 of 5 stars$175.98+1.0%$220.67+25.4%+26.7%$10.65B$393.54M-28.021,017Positive NewsBBIOBridgeBio Pharma4.6381 of 5 stars$43.50-1.1%$58.85+35.3%+75.8%$8.35B$221.90M-12.32400News CoverageAnalyst ForecastAnalyst RevisionBPMCBlueprint Medicines1.0968 of 5 stars$128.40+0.0%$128.06-0.3%+9.8%$8.29B$508.82M-51.98640Positive News Related Companies and Tools Related Companies Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Moderna Alternatives Regencell Bioscience Alternatives Viatris Alternatives QIAGEN Alternatives Ascendis Pharma A/S Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKRO) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKRO Stock Alerts